Legend Biotech/$LEGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Legend Biotech
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Ticker
$LEGN
Sector
Primary listing
Employees
3,100
Headquarters
Website
Legend Biotech Metrics
BasicAdvanced
$5.2bn
-
-$1.38
0.35
-
Price and volume
Market cap
$5.2bn
Beta
0.35
52-week high
$45.30
52-week low
$16.24
Average daily volume
3m
Financial strength
Current ratio
2.127
Quick ratio
1.643
Long term debt to equity
11.584
Total debt to equity
40.229
Interest coverage (TTM)
-6.57%
Profitability
EBITDA (TTM)
-125.1
Gross margin (TTM)
54.99%
Net profit margin (TTM)
-21.96%
Operating margin (TTM)
-11.82%
Effective tax rate (TTM)
-5.75%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
-5.24%
Return on equity (TTM)
-25.19%
Valuation
Price to revenue (TTM)
4.528
Price to book
5.36
Price to tangible book (TTM)
5.36
Price to free cash flow (TTM)
-44.538
Free cash flow yield (TTM)
-2.25%
Free cash flow per share (TTM)
-0.627
Growth
Revenue change (TTM)
56.39%
Earnings per share change (TTM)
15.95%
3-year revenue growth (CAGR)
116.65%
3-year earnings per share growth (CAGR)
-24.43%
What the Analysts think about Legend Biotech
Analyst ratings (Buy, Hold, Sell) for Legend Biotech stock.
Legend Biotech Financial Performance
Revenues and expenses
Legend Biotech Earnings Performance
Company profitability
Legend Biotech News
AllArticlesVideos
Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga·2 days ago
Legend's experimental cell therapy shows promise in blood cancer patients
Reuters·3 weeks ago
Legend Biotech Conference Spotlights CARVYKTI's Curative Potential, Earlier Use
MarketBeat·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs